Treatment of Menière’s Disease

Current Treatment Options in Neurology

Volumn 17, Issue 4, 2015, Pages

  Sharon, Jeffrey D ^a   Trevino, Carolina ^a   Schubert, Michael C ^a   Carey, John P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Intratympanic gentamicin; Intratympanic steroids; Meniere s disease; Pharmacotherapy for Meniere s disease; Unilateral hearing loss; Vertigo; Vestibular physical therapy

Indexed keywords

ANTIEMETIC AGENT; BENZODIAZEPINE DERIVATIVE; BETAHISTINE; CAFFEINE; DIAZEPAM; DIURETIC AGENT; GENTAMICIN; STEROID;

AUDIOMETRY; CLINICAL TRIAL (TOPIC); CONTRAST ENHANCEMENT; DIET; ENDOLYMPHATIC SAC; EXERCISE; GENERAL DEVICE; HEARING AID; HUMAN; INNER EAR DISEASE; INTERNAL AUDITORY CANAL; LABYRINTHECTOMY; LIFESTYLE; LYME DISEASE; MEDICAL HISTORY; MENIERE DISEASE; MENIETT DEVICE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCEPTION DEAFNESS; PERILYMPH FISTULA; PHYSIOTHERAPY; REVIEW; SEMICIRCULAR CANAL; SLEEP; SODIUM RESTRICTION; SPEECH THERAPY; STRESS; TEMPORAL BONE TUMOR; TINNITUS; UNILATERAL HEARING LOSS; VERTIGO; VESTIBULAR FUNCTION; VESTIBULAR NERVE;

EID: 84924388839     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-015-0341-x     Document Type: Review

References (69)

1. Baloh RW. Prosper Meniere and his disease. Arch Neurol. 2001;58(7):1151–6.
2. Monsell EM et al. Committee on hearing and equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere’s disease. Otolaryngol Head Neck Surg. 1995;113(3):181–5. This article established commonly used guidelines for diagnosing Menière’s disease and evaluating treatment efficacy.
3. Society B. Diagnostic criteria for Menière’s disease. Available from: http://www.jvr-web.org/images/55807-Lopez-Escamez.pdf
4. Rauch SD, Merchant SN, Thedinger BA. Meniere’s syndrome and endolymphatic hydrops. Double-blind temporal bone study. Ann Otol Rhinol Laryngol. 1989;98(11):873–83. A temporal bone study that helped clarify the relationship of histological endolymphatic hydrops and clinical Menière’s disease.
5. Rauch SD et al. Vestibular evoked myogenic potentials show altered tuning in patients with Meniere’s disease. Otol Neurotol. 2004;25(3):333–8.
6. Zuniga MG et al. Can vestibular-evoked myogenic potentials help differentiate Meniere disease from vestibular migraine? Otolaryngol Head Neck Surg. 2012;146(5):788–96.
7. Hornibrook J et al. Transtympanic electrocochleography for the diagnosis of Meniere’s disease. Int J Otolaryngol. 2012;2012:852714.
8. Claes GM et al. The Meniere’s disease index: an objective correlate of Meniere’s disease, based on audiometric and electrocochleographic data. Otol Neurotol. 2011;32(5):887–92.
9. Nakashima T et al. Visualization of endolymphatic hydrops in patients with Meniere’s disease. Laryngoscope. 2007;117(3):415–20. This important paper showed that it was possible to visualize endolymphatic hydrops in Menière’s disease using high resolution MRI and intratympanic contrast.
10. Pyykko I et al. Magnetic resonance imaging of the inner ear in Meniere’s disease. Otolaryngol Clin North Am. 2010;43(5):1059–80.
11. Gurkov R et al. Herniation of the membranous labyrinth into the horizontal semicircular canal is correlated with impaired caloric response in Meniere’s disease. Otol Neurotol. 2012;33(8):1375–9. This study is important because it showed that novel MRI techniques used to visualize endolymphatic hydrops in vivo do correlate with objective measures like vestibular testing.
12. Gurkov R et al. In vivo visualization of endolymphatic hydrops in patients with Meniere’s disease: correlation with audiovestibular function. Eur Arch Otorhinolaryngol. 2011;268(12):1743–8.
13. Kinney SE, Sandridge SA, Newman CW. Long-term effects of Meniere’s disease on hearing and quality of life. Am J Otol. 1997;18(1):67–73.
14. Sajjadi H, Paparella MM. Meniere’s disease. Lancet. 2008;372(9636):406–14.
15. Minor LB, Schessel DA, Carey JP. Meniere’s disease. Curr Opin Neurol. 2004;17(1):9–16.
16. Smith WK, Sankar V, Pfleiderer AG. A national survey amongst UK otolaryngologists regarding the treatment of Meniere’s disease. J Laryngol Otol. 2005;119(2):102–5.
17. Greenberg SL, Nedzelski JM. Medical and noninvasive therapy for Meniere’s disease. Otolaryngol Clin North Am. 2010;43(5):1081–90.
18. Thirlwall AS, Kundu S. Diuretics for Meniere’s disease or syndrome. Cochrane Database Syst Rev. 2006;3:CD003599.
19. van Deelen GW, Huizing EH. Use of a diuretic (Dyazide) in the treatment of Meniere’s disease. A double-blind cross-over placebo-controlled study. ORL J Otorhinolaryngol Relat Spec. 1986;48(5):287–92.
20. Ihler F et al. Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo. PLoS One. 2012;7(6):e39086.
21. James AL and Burton MJ. Betahistine for Meniere’s disease or syndrome. Cochrane Database Syst Rev. 2001(1):CD001873. This systematic review examined the evidence for betahistine, which is widely used around the world as a treatment for Menière’s disease.
22. Strupp M et al. Long-term prophylactic treatment of attacks of vertigo in Meniere’s disease—comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol. 2008;128(5):520–4.
23. Lezius F et al. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Meniere’s disease: a case series. Eur Arch Otorhinolaryngol. 2011;268(8):1237–40.
24. Rauch SD et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA. 2011;305(20):2071–9.
25. Pondugula SR et al. Glucocorticoids stimulate cation absorption by semicircular canal duct epithelium via epithelial sodium channel. Am J Physiol Renal Physiol. 2004;286(6):F1127–35.
26. Garduno-Anaya MA et al. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Meniere’s disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg. 2005;133(2):285–94. A well-conducted trial that helped establish the utility of intratympanic steroids as a treatment for Menière’s disease.
27. Phillips JS and Westerberg B. Intratympanic steroids for Meniere’s disease or syndrome. Cochrane Database Syst Rev. 2011(7):CD008514. Systematic review that looked at evidence for intratympanic steroids in treating Menière’s disease.
28. Boleas-Aguirre MS et al. Longitudinal results with intratympanic dexamethasone in the treatment of Meniere’s disease. Otol Neurotol. 2008;29(1):33–8.
29. Casani AP et al. Intratympanic treatment of intractable unilateral Meniere disease: gentamicin or dexamethasone? A randomized controlled trial. Otolaryngol Head Neck Surg. 2012;146(3):430–7.
30. Lyford-Pike S et al. Gentamicin is primarily localized in vestibular type I hair cells after intratympanic administration. J Assoc Res Otolaryngol. 2007;8(4):497–508. This animal study showed the differential uptake of gentamicin by type 1 vestibular hair cells.
31. Carey JP et al. Changes in the three-dimensional angular vestibulo-ocular reflex following intratympanic gentamicin for Meniere’s disease. J Assoc Res Otolaryngol. 2002;3(4):430–43. This study examined the physiologic changes that occurred to the vestibulo-ocular reflex after gentamicin administration.
32. Stokroos R, Kingma H. Selective vestibular ablation by intratympanic gentamicin in patients with unilateral active Meniere’s disease: a prospective, double-blind, placebo-controlled, randomized clinical trial. Acta Otolaryngol. 2004;124(2):172–5. A placebo controlled study that added to the body of literature establishing the effectiveness of gentamicin in treating Menière’s disease.
33. Postema RJ et al. Intratympanic gentamicin therapy for control of vertigo in unilateral Meniere’s disease: a prospective, double-blind, randomized, placebo-controlled trial. Acta Otolaryngol. 2008;128(8):876–80. Another well conducted study that showed the effectiveness of gentamicin for treating Menière’s disease.
34. Wu IC, Minor LB. Long-term hearing outcome in patients receiving intratympanic gentamicin for Meniere’s disease. Laryngoscope. 2003;113(5):815–20.
35. Nguyen KD et al. Time course of repeated intratympanic gentamicin for Meniere’s disease. Laryngoscope. 2009;119(4):792–8.
36. Perez R, Chen JM, Nedzelski JM. The status of the contralateral ear in established unilateral Meniere’s disease. Laryngoscope. 2004;114(8):1373–6.
37. Crane BT et al. Middle ear exploration in patients with Meniere’s disease who have failed outpatient intratympanic gentamicin therapy. Otol Neurotol. 2009;30(5):619–24.
38. Satoh H et al. Proinflammatory cytokine expression in the endolymphatic sac during inner ear inflammation. J Assoc Res Otolaryngol. 2003;4(2):139–47.
39. Portmann G. The saccus endolymphaticus and an operation for draining for the relief of vertigo. Proc R Soc Med. 1927;20(12):1862–7.
40. Sood AJ et al. Endolymphatic sac surgery for Meniere’s disease: a systematic review and meta-analysis. Otol Neurotol. 2014;35(6):1033–45. A systematic review that examined the evidence for endolymphatic sac surgery in Menière's diease.
41. Pullens B, Verschuur HP, van Benthem PP. Surgery for Meniere’s disease. Cochrane Database Syst Rev. 2013;2:CD005395.
42. Welling DB, Nagaraja HN. Endolymphatic mastoid shunt: a reevaluation of efficacy. Otolaryngol Head Neck Surg. 2000;122(3):340–5.
43. Chung JW et al. Histopathology after endolymphatic sac surgery for Meniere’s syndrome. Otol Neurotol. 2011;32(4):660–4.
44. Brinson GM, Chen DA, Arriaga MA. Endolymphatic mastoid shunt versus endolymphatic sac decompression for Meniere’s disease. Otolaryngol Head Neck Surg. 2007;136(3):415–21.
45. Minor LB. Intratympanic gentamicin for control of vertigo in Meniere’s disease: vestibular signs that specify completion of therapy. Am J Otol. 1999;20(2):209–19.
46. Goksu N et al. Combined retrosigmoid retrolabyrinthine vestibular nerve section: results of our experience over 10 years. Otol Neurotol. 2005;26(3):481–3.
47. Lustig LR et al. Cochlear implantation in patients with bilateral Meniere’s syndrome. Otol Neurotol. 2003;24(3):397–403.
48. Hillier SL and McDonnell M. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database Syst Rev. 2011(2):CD005397. A systematic review that provided strong evidence that vestibular physical therapy is helpful in Menière’s disease.
49. Schubert MC et al. Mechanism of dynamic visual acuity recovery with vestibular rehabilitation. Arch Phys Med Rehabil. 2008;89(3):500–7. An important study that helped elucidate the physiologic changes that occur with vestibular physical therapy.
50. Schubert MC et al. Oculomotor strategies and their effect on reducing gaze position error. Otol Neurotol. 2010;31(2):228–31.
51. Scherer M, Migliaccio AA, Schubert MC. Effect of vestibular rehabilitation on passive dynamic visual acuity. J Vestib Res. 2008;18(2–3):147–57.
52. Hall CD, Schubert MC, Herdman SJ. Prediction of fall risk reduction as measured by dynamic gait index in individuals with unilateral vestibular hypofunction. Otol Neurotol. 2004;25(5):746–51.
53. McDonnell MN, Hillier SL. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database Syst Rev. 2015;1:CD005397.
54. Garcia AP et al. Vestibular rehabilitation with virtual reality in Meniere’s disease. Braz J Otorhinolaryngol. 2013;79(3):366–74. This study is important because it highlighted the use of virtual reality to deliver vestibular rehabilitation therapy to Menière’s patient, and showed it to be highly effective.
55. Herdman SJ et al. Recovery of dynamic visual acuity in bilateral vestibular hypofunction. Arch Otolaryngol Head Neck Surg. 2007;133(4):383–9.
56. Herdman SJ et al. Recovery of dynamic visual acuity in unilateral vestibular hypofunction. Arch Otolaryngol Head Neck Surg. 2003;129(8):819–24.
57. Syed MI et al. Positive pressure therapy for Meniere’s syndrome/ disease with a Meniett device: A systematic review of randomised controlled trials. Clin Otolaryngol. 2014. A systematic review that examined the evidence for the Meniett device.
58. Ahsan SF, Standring R and Wang Y. Systematic review and meta-analysis of Meniett therapy for Meniere’s disease. Laryngoscope. 2014. Another systematic review that looked at evidence for the Meniett device
59. Lambert PR et al. A randomized, double-blind, placebo-controlled clinical study to assess safety and clinical activity of OTO-104 given as a single intratympanic injection in patients with unilateral Meniere's disease. Otol Neurotol. 2012;33(7):1257–65. This study is important because it examined a novel delivery vehicle for intratympanic dexamethesone, which has been proven to be an effective, non-ablative treatment.
60. ClinicalTrials.gov. OTO-104 for the Treatment of Meniere’s Disease. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01412177?term=meniere%27s&rank=4
61. Stahle J, Stahle C, Arenberg IK. Incidence of Meniere’s disease. Arch Otolaryngol. 1978;104(2):99–102.
62. Meyerhoff WL, Paparella MM, Shea D. Meniere’s disease in children. Laryngoscope. 1978;88(9 Pt 1):1504–11.
63. Filipo R, Barbara M. Juvenile Meniere’s disease. J Laryngol Otol. 1985;99(2):193–6.
64. Hausler R et al. Meniere’s disease in children. Am J Otolaryngol. 1987;8(4):187–93.
65. Akagi H et al. Meniere’s disease in childhood. Int J Pediatr Otorhinolaryngol. 2001;61(3):259–64.
66. Medicine, O.C.f.E.B. Levels of Evidence. 2009 [cited 2015 Jan 16]; Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
67. Diaz RC et al. Quality-of-life assessment of Meniere’s disease patients after surgical labyrinthectomy. Otol Neurotol. 2007;28(1):74–86.
68. Syed I, Aldren C. Meniere’s disease: an evidence based approach to assessment and management. Int J Clin Pract. 2012;66(2):166–70.
69. Rauch SD. Clinical hints and precipitating factors in patients suffering from Meniere’s disease. Otolaryngol Clin North Am. 2010;43(5):1011–7.